Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Exp Pharmacol Physiol ; 40(12): 856-63, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24256163

ABSTRACT

The cardiac persistent sodium current (IN aP ) presents a novel target for cardiac ischaemic protection. Herein we investigated the effects of the IN aP blocker riluzole in a pig model of regional myocardial ischaemia. Landrace or Large White pigs were subjected to 3 h ligation of the left anterior descending coronary artery (LAD). Pigs received either saline (500 mL/h, i.v.) throughout the experiment (control; n = 7) or riluzole (2 mg/kg in 2 mL propylene glycol in 100 mL saline, i.v.; RIL; n = 7) between 15 and 5 min prior to ligation. The arrhythmia score was calculated in 5 min epochs. Myocardial damage was assessed using epicardial image analysis and histological sectioning. In the control group, all seven pigs developed premature ventricular contractions (PVC), seven developed non-sustained arrhythmias and six of seven developed sustained arrhythmias. Of the sustained arrhythmias, 23 of 28 instances were initiated by R-on-T extrasytoles (extrasystoles within the vulnerable period that can trigger re-entrant arrhythmias). In the RIL group, all seven pigs developed PVC, six of seven developed non-sustained arrhythmias and only three developed sustained arrhythmias, of which two of five instances were R-on-T initiated. The riluzole-treated pigs exhibited less myocardial damage than pigs in the control group (65% smaller surface area (P = 0.008) on gross epicardial inspection, 51% less oedema (P = 0.01), 53% less fibre waviness (P = 0.029) assessed by haematoxylin and eosin staining and 79% fewer fragmented nuclei (P = 0.009) assessed by terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end-labelling). In conclusion, riluzole significantly reduced Phase 2 (the period associated with irreversible damage) ischaemic R-on-T triggered and non-R-on-T arrhythmias and myocardial damage occurring during the 3 h period of regional ischaemia.


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Arrhythmias, Cardiac/prevention & control , Coronary Occlusion/drug therapy , Myocardial Ischemia/drug therapy , Myocardium/pathology , Riluzole/therapeutic use , Sodium Channel Blockers/therapeutic use , Animals , Anti-Arrhythmia Agents/administration & dosage , Arrhythmias, Cardiac/etiology , Arrhythmias, Cardiac/metabolism , Arrhythmias, Cardiac/pathology , Coronary Occlusion/complications , Coronary Occlusion/metabolism , Coronary Occlusion/pathology , Disease Models, Animal , Electrocardiography , Female , Male , Myocardial Ischemia/complications , Myocardial Ischemia/metabolism , Myocardial Ischemia/pathology , Myocardium/metabolism , Riluzole/administration & dosage , Sodium Channel Blockers/administration & dosage , Swine
2.
PLoS One ; 5(11): e14103, 2010 Nov 24.
Article in English | MEDLINE | ID: mdl-21124787

ABSTRACT

BACKGROUND: The potential of the cardiac persistent sodium current as a target for protection of the myocardium from ischaemia and reperfusion injury is gaining increasing interest. We have investigated the anti-ischaemic and antiarrhythmic effects of riluzole, a selective INaP blocker, in an open chest pig model of infarction. METHODS AND PRINCIPAL FINDINGS: The left anterior descending coronary artery (LAD) was ligated in 27 anesthetised pigs (landrace or large white, either sex, 20-35 kg) which had received riluzole (8 mg/kg IP; n = 6), lidocaine (2.5-12 mg/kg bolus plus 0.05-0.24 mg/kg/min; n = 11) or vehicle (n = 10) 50 min prior. Arrhythmias could be delineated into phase 1a (0 to 20 min), phase 1b (20 to 50 min) and phase 2 (from 50 min to termination at 180 min) and were classified as premature ventricular contractions (PVCs), non-sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) (spontaneously reverting within 15 s) or sustained VT or VF (ie. requiring cardioversion at 15 s). Riluzole reduced the average number of all arrhythmias in Phase 2 (PVCs from 484+/-119 to 32+/-13; non sustained arrhythmias from 8.9+/-4.4 to 0.7+/-0.5; sustained arrhythmias from 3.9+/-2.2 to 0.5+/-0.4); lidocaine reduced the average number of non-sustained and sustained arrhythmias (to 0.4+/-0.3 and 0.4+/-0.3 respectively) but not PVCs (to 390+/-234). Riluzole and lidocaine reduced the average number of sustained arrhythmias in phase 1b (from 1.8+/-0.4 to 0.17+/-0.13 (p<0.02) and to 0.55+/-0.26 (p = ns) respectively). Neither lidocaine or riluzole changed the ECG intervals: there was no statistical significance between groups at time zero (just before ligation) for any ECG measure. During the course of the 3 hour period of the ischaemia R-R, and P-R intervals shortened slightly in control and riluzole groups (not significantly different from each other) but not in the lidocaine group (significantly different from control). QRS and QTc did not change appreciably in any group Riluzole reduced the degree of histopathological tissue damage across the infarct zone considerably more than did lidocaine. CONCLUSIONS: At the doses used, riluzole was at least as effective as lidocaine at reducing the number of episodes of ischaemic VT or VF in pigs, and much more effective at reducing the number of PVCs. We propose that this is related to the ability of riluzole to block cardiac persistent sodium current.


Subject(s)
Arrhythmias, Cardiac/prevention & control , Myocardial Infarction/prevention & control , Myocardial Ischemia/prevention & control , Riluzole/pharmacology , Sodium Channel Blockers/pharmacology , Animals , Anti-Arrhythmia Agents/pharmacology , Arrhythmias, Cardiac/physiopathology , Electrocardiography , Female , Heart/drug effects , Heart/physiopathology , Lidocaine/pharmacology , Male , Myocardial Infarction/physiopathology , Myocardial Ischemia/physiopathology , Myocardium/pathology , Neuroprotective Agents/pharmacology , Swine
3.
Postgrad Med ; 97(6): 56-67, 1995 Jun.
Article in English | MEDLINE | ID: mdl-29211570

ABSTRACT

Preview No physician would treat hypertension without monitoring blood pressure, but some treat bronchial asthma without objectively measuring pulmonary function. This empirical approach is inappropriate, according to the authors, who discuss key measurements that should be taken to assess disease status, guide therapy, and monitor response. Three illustrative cases stress the importance of objective evaluation of asthma.

SELECTION OF CITATIONS
SEARCH DETAIL
...